%DA%A9%D8%A7%D8%A8%D8%A7%D8%B2%DB%8C%D8%AA%D8%A7%DA%A9%D8%B3%D9%84CabazitaxelCabazitaxelCabazitaxel%DA%A9%D8%A7%D8%A8%D8%A7%D8%B2%DB%8C%D8%AA%D8%A7%DA%A9%D8%B3%D9%84Cabazitaxel%E3%82%AB%E3%83%90%E3%82%B8%E3%82%BF%E3%82%AD%E3%82%BB%E3%83%ABCabazitaxelKabazytakselCabazitaxelCabazitaxelKabazitakselKabazitaksel%D0%9A%D0%B0%D0%B1%D0%B0%D0%B7%D0%B8%D1%82%D0%B0%D0%BA%D1%81%D0%B5%D0%BBCabazitaxelQ412963
about
sameAs
P3354
P3781
Emerging treatment options for patients with castration-resistant prostate cancer.Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: a practical solution for non-specific binding.MDV3100 for the treatment of prostate cancer.Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.Cabazitaxel for the treatment of prostate cancer.Contemporary management of metastatic castration-resistant prostate cancer.Current treatment strategies for castration-resistant prostate cancerClinical development of cabazitaxel for the treatment of castration-resistant prostate cancerRecent advances in second-line treatment of castration-resistant prostate cancer.Cabazitaxel: a novel microtubule inhibitor.Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel settingSynergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells.Cabazitaxel for the treatment of castration-resistant prostate cancer.TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.Cabazitaxel-Loaded Nanocarriers for Cancer Therapy with Reduced Side EffectsInterim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practThe efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patientsTherapeutic Effect of Cabazitaxel and Blood-Brain Barrier opening in a Patient-Derived Glioblastoma ModelA multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study
P921
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Cabazitaxel
@de
Cabazitaxel
@es
Cabazitaxel
@nl
Cabazitaxel
@ro
Cabazitaxel
@vi
Kabazitaksel
@sh
Kabazitaksel
@sr
cabazitaxel
@en
cabazitaxel
@fr
cabazitaxel
@pt
type
label
Cabazitaxel
@de
Cabazitaxel
@es
Cabazitaxel
@nl
Cabazitaxel
@ro
Cabazitaxel
@vi
Kabazitaksel
@sh
Kabazitaksel
@sr
cabazitaxel
@en
cabazitaxel
@fr
cabazitaxel
@pt
altLabel
Cabazitaxel
@en
Cabazitaxelum
@en
Jevanta®
@en
Jevtana
@pt
TXD 258
@en
TXD258
@en
Taxoid XRP6258
@en
XRP-6258
@en
XRP6258
@en
XRP6258
@pt
prefLabel
Cabazitaxel
@de
Cabazitaxel
@es
Cabazitaxel
@nl
Cabazitaxel
@ro
Cabazitaxel
@vi
Kabazitaksel
@sh
Kabazitaksel
@sr
cabazitaxel
@en
cabazitaxel
@fr
cabazitaxel
@pt